MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.05
+0.15
+2.54%
Closed 16:00 05/25 EDT
OPEN
5.95
PREV CLOSE
5.90
HIGH
6.07
LOW
5.73
VOLUME
16.07K
TURNOVER
72.36K
52 WEEK HIGH
10.50
52 WEEK LOW
3.940
MARKET CAP
42.37M
P/E (TTM)
-5.9290
1D
5D
1M
3M
1Y
5Y
BRIEF-Caligan Partners Lp Reports 5.9% Stake In Alimera Sciences As Of May 19, 2022 - SEC Filing
reuters.com · 1h ago
Alimera Sciences Announces Phase 4 PALADIN Study On Predictive Value Of Corticosteroid Course Prior To ILUVIEN Use For IOP Outcomes
Alimera Sciences, Inc. (NASDAQ:ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better
Benzinga · 05/12 12:16
Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes
Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choiceATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical com...
GlobeNewswire · 05/12 12:03
--HC Wainwright Adjusts Alimera Sciences' Price Target to $8 from $10, Keeps Buy Rating
MT Newswires · 05/10 09:23
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 13:15
Recap: Alimera Sciences Q1 Earnings
  Alimera Sciences (NASDAQ:ALIM) reported its Q1 earnings results on Monday, May 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/09 12:52
Alimera Sciences Q1 EPS $(0.85) Misses $(0.69) Estimate, Sales $11.90M Miss $12.90M Estimate
Alimera Sciences (NASDAQ:ALIM) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.69) by 23.19 percent. This is a 34.92 percent decrease over losses of $(0.63) per share
Benzinga · 05/09 12:18
Alimera Sciences GAAP EPS of -$0.85 misses by $0.16, revenue of $11.89M misses by $1.01M
Alimera Sciences press release (NASDAQ:ALIM): Q1 GAAP EPS of -$0.85 misses by $0.16. Revenue of $11.89M (+6.1% Y/Y) misses by $1.01M.
Seekingalpha · 05/09 12:03
More
No Data
Learn about the latest financial forecast of ALIM. Analyze the recent business situations of Alimera Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALIM stock price target is 12.33 with a high estimate of 18.00 and a low estimate of 8.00.
High18.00
Average12.33
Low8.00
Current 6.05
EPS
Actual
Estimate
-0.410.020.460.89
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 49
Institutional Holdings: 31.59M
% Owned: 451.10%
Shares Outstanding: 7.00M
TypeInstitutionsShares
Increased
1
490.00K
New
2
251.96K
Decreased
4
6.89K
Sold Out
5
634.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.11%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman
C. Daniel Myers
President/Chief Executive Officer/Director
Richard Eiswirth
Chief Financial Officer
J. Phillip Jones
Chief Operating Officer/Senior Vice President
Philip Ashman
Senior Vice President/Chief Marketing Officer
David Holland
Lead Director/Independent Director
James Largent
Director
Erin Parsons
Independent Director
Brian Halak
Independent Director
Garheng Kong
Independent Director
Peter Pizzo
Independent Director
John Snisarenko
No Data
No Data
About ALIM
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.